Endocrine Abstracts

Objectives: Vandetanib (V) is an important drug in the metastatic medullary thyroid cancer (MTC) treatment. The objective of this study was to evaluate the presence of predictors of V response, in short and long period, in locally advanced or metastatic MTC patients (pts).Methods: Seventy-nine locally advanced or metastatic MTC pts with progressive or symptomatic disease, referred to our Center between 2007 and 2018 and already treated surgically and wit...

Background: CV-PTC is often indolent with excellent long-term response, while TCV-PTC (≥50% of tall cells) have aggressive features and worse clinical behavior. Less is known about the clinical behavior of CV-PTC with tall cells <50% (TC/CV-PTC) that, so far, is considered as low risk tumor.Aim: To evaluate the histological presentation of CV-PTC, TC/CV-PTC, TCV-PTC and their clinical behavior after 6 years of follow up.M...

Objectives: The majority of patients with differentiated thyroid carcinoma (TC) have an excellent prognosis, with a 5-year survival rate of 98.3%, and only rarely reaches an advanced stage of disease. The present study aims to identify the clinicopathological and epidemiological features at the time of diagnosis of a group of patients who required to be treated with systemic therapy with tyrosine-kinase inhibitors (TKI).Methods: We retrospectively evalua...

Background and Aim: American Thyroid Association (ATA) guidelines do not consider age at diagnosis of differentiated thyroid cancer (DTC) as a prognostic factor in the estimation of risk of recurrence and persistent disease. While age at diagnosis has already been assessed in high-risk patients, it remains to be established whether there is a correlation between age at diagnosis and long term outcome in DTC patients.Methods: We retrospectively evaluated ...

Objective: Recent studies have shown that sarcopenia at cancer diagnosis is associated with a poor survival in patients with solid tumors. Up to now, few data are available among patients with advanced thyroid cancer, especially those treated with tyrosine kinase inhibitors (TKI). We retrospectively evaluated sarcopenia by Skeletal Muscle Index (SMI) in a cohort of advanced thyroid cancer patients before and during TKI treatment and investigated its association with treatment ...

Introduction and Objective: The initial assessment of differentiated thyroid cancer (DTC) patients is based on the American Thyroid Association (ATA) risk stratification criteria. Dynamic risk stratification (DRS) of DTC patients takes into consideration the response to initial treatment being reassessed at 1–2 years and revealed significant shifts in the risk categories of DTC patients. We aimed to evaluate the long-term outcome of papillary thyroid cancer (PTC) patients...